AI assistant
Sending…
CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2021
Jul 8, 2021
31542_dirs_2021-07-08_db1d79a6-b63b-4a3c-8004-7e4a46c3f72c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2021-06-29
Reporting Person: Harper Molly (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Options to purchase Common Stock | $5.78 | 2028-06-29 | Common Stock (60000) | Direct |
Footnotes
F1: Options will vest in three equal tranches on June 29, 2022, 2023 and 2024.
More from CATALYST PHARMACEUTICALS, INC.
M&A Activity
2026
Jun 8
Report Publication Announcement
2026
May 11
M&A Activity
2026
May 7
Major Shareholding Notification
2026
Mar 26
Earnings Release
2026
Feb 25
Annual Report
2026
Feb 25
Director's Dealing
2026
Feb 19
Investor Presentation
2026
Jan 12
Director's Dealing
2026
Jan 6
Director's Dealing
2026
Jan 6